These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 29899890)

  • 1. Pharmacokinetic-based prediction of real-life dosing of extended half-life clotting factor concentrates on hemophilia.
    Morfini M; Gherardini S
    Ther Adv Hematol; 2018 Jun; 9(6):149-162. PubMed ID: 29899890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic and safety considerations when switching from standard to extended half-life clotting factor concentrates in hemophilia.
    Morfini M; Farrugia A
    Expert Rev Hematol; 2019 Oct; 12(10):883-892. PubMed ID: 31314609
    [No Abstract]   [Full Text] [Related]  

  • 4. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: Lessons learned with the CHO-KLAT tool.
    Carcao M; Zunino L; Young NL; Dover S; Bouskill V; Hilliard P; Price VE; Blanchette VS
    Haemophilia; 2020 Jan; 26(1):73-78. PubMed ID: 31865620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A.
    Batorova A; Boban A; Brinza M; Lissitchkov T; Nemes L; Zupan Preložnik I; Smejkal P; Zozulya N; Windyga J
    J Med Life; 2022 Apr; 15(4):570-578. PubMed ID: 35646171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
    Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
    Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients.
    Yu JK; Iorio A; Edginton AN
    Thromb Res; 2020 Dec; 196():550-558. PubMed ID: 33157394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico comparison of pharmacokinetic properties of three extended half-life factor IX concentrates.
    Preijers T; Bukkems L; van Spengler M; Leebeek F; Cnossen M; Mathôt R
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1193-1200. PubMed ID: 33624121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Australian experience with switching to extended half-life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation.
    Brennan Y; Parikh S; McRae S; Tran H
    Haemophilia; 2020 May; 26(3):529-535. PubMed ID: 32243027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics.
    Nummi V; Lehtinen AE; Iorio A; Szanto T; Lassila R
    Haemophilia; 2022 Nov; 28(6):e237-e244. PubMed ID: 35939628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: Data from the WAPPS database.
    Versloot O; Iserman E; Chelle P; Germini F; Edginton AN; Schutgens REG; Iorio A; Fischer K;
    J Thromb Haemost; 2021 Aug; 19(8):1896-1906. PubMed ID: 34013558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simoctocog alfa for the treatment of hemophilia A.
    Morfini M
    Expert Opin Biol Ther; 2017 Dec; 17(12):1573-1580. PubMed ID: 29050497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients.
    Preijers T; van Spengler MWF; Meijer K; Fijnvandraat K; Fischer K; Leebeek FWG; Cnossen MH; Mathôt RAA
    Eur J Clin Pharmacol; 2022 Feb; 78(2):237-249. PubMed ID: 34651201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 18. Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).
    Goedhart TMHJ; Bukkems LH; Coppens M; Fijnvandraat KJ; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
    TH Open; 2022 Jan; 6(1):e60-e69. PubMed ID: 35280975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies.
    Di Minno MND; Di Minno A; Calcaterra I; Cimino E; Dell'Aquila F; Franchini M
    Semin Thromb Hemost; 2021 Feb; 47(1):32-42. PubMed ID: 33348412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The History of Clotting Factor Concentrates Pharmacokinetics.
    Morfini M
    J Clin Med; 2017 Mar; 6(3):. PubMed ID: 28335525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.